Risks and benefits of anticoagulation in atrial fibrillation: Insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry

Michael W. Cullen, Sunghee Kim, Jonathan P. Piccini, Jack E. Ansell, Greg C. Fonarow, Elaine M. Hylek, Daniel E. Singer, Kenneth W. Mahaffey, Peter R. Kowey, Laine Thomas, Alan S. Go, Renato D. Lopes, Paul Chang, Eric D. Peterson, Bernard J. Gersh

Research output: Contribution to journalArticlepeer-review

Abstract

Background-Patients with atrial fibrillation (AF) at the highest stroke risk derive the largest benefit from oral anticoagulation (OAC). Those with the highest stroke risk have been paradoxically less likely to receive OAC. This study assessed the association between stroke and bleeding risk on rates of OAC. Methods and Results-We analyzed OAC use among 10 098 patients with AF from 174 community-based outpatient practices enrolled in 2010-2011 in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBITAF). OAC was defined as warfarin or dabigatran use at study enrollment. Stroke and bleeding risk were calculated using congestive heart failure, hypertension, age, diabetes mellitus, prior stroke (CHADS2), and anticoagulation and risk factors in AF (ATRIA) scores, respectively. The mean subject age was 73 years; 58% were men. Overall, 76% of patients received OAC (71% warfarin and 5% dabigatran). The use of OAC increased among those with higher CHADS2 scores, from 53% for CHADS2=0 to 80% for CHADS22 (P<0.001). OAC use fell slightly with increasing ATRIA bleeding risk score, from 81% for ATRIA=3 to 73% for ATRIA≥5 (P<0.001). A significant interaction existed between ATRIA and CHADS2 scores (P=0.021). Among those with low bleeding risk, use of OAC increased significantly with increasing stroke risk. Among those with high bleeding risk, CHADS2 stroke risk had a smaller impact on use of OAC. Conclusions-In community-based outpatients with AF, use of OAC was high and driven by not only predominantly stroke but also bleeding risk. Stroke risk significantly affects OAC use among those with low bleeding risk, whereas those with high bleeding risk demonstrate consistently lower use of OAC regardless of stroke risk.

Original languageEnglish (US)
Pages (from-to)461-469
Number of pages9
JournalCirculation: Cardiovascular Quality and Outcomes
Volume6
Issue number4
DOIs
StatePublished - Jul 2013
Externally publishedYes

Keywords

  • Anticoagulants
  • Atrial fibrillation
  • Hemorrhage
  • Risk factors
  • Stroke prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Risks and benefits of anticoagulation in atrial fibrillation: Insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry'. Together they form a unique fingerprint.

Cite this